Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.CLINICAL TRIALS